Health Science Technology

Business

IDEX Beats Q4 Expectations on Surging Health & Science Demand, Charts Cautious 2026 Course

IDEX Corporation capped off fiscal 2025 with stronger-than-anticipated fourth-quarter results, propelled by a record-setting order surge in its Health & Science Technologies unit linked to data center and AI infrastructure. While management expressed confidence in its strategic evolution, it offered a measured outlook for the coming year amid a mixed industrial landscape.

Feb 5, 2026

Business

Healthpeak Navigates Life Science Headwinds with Strong Outpatient and Senior Housing Performance; Announces Senior Housing REIT Spin-Off

Healthpeak Properties reported resilient fourth-quarter results, driven by strength in its Outpatient Medical and Senior Housing segments, which helped counter a prolonged downturn in Life Science. The company announced a major portfolio repositioning, including a strategic lab acquisition and plans to spin off its Senior Housing portfolio into a new publicly traded REIT, Janus Living.

Feb 4, 2026

Business

RoundTable Healthcare Partners Acquires Colorescience, Bolstering Portfolio with Fast-Growing Skincare Brand

Private equity firm RoundTable Healthcare Partners has acquired the dermatologist-trusted skincare and sun protection brand Colorescience from 1315 Capital, as the company's annual sales approach the $100 million mark.

Feb 2, 2026

Business

IDEX Beats Q4 Estimates as Data Center Boom and Health Tech Fuel Growth

Industrial manufacturer IDEX surpassed Wall Street's revenue and profit forecasts for the fourth quarter, driven by robust demand in its Health, Science & Technology unit and key investments in data center infrastructure.

Feb 5, 2026

Business

Edwards Lifesciences Halts JenaValve Acquisition, Doubles Down on Core Valve Technology

Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.

Feb 2, 2026

Business

GE HealthCare Posts $20.6B in FY25 Revenue, Fueled by Sustained Demand for Imaging Technology

The medtech giant surpassed financial expectations, driven by robust performance in its core imaging and pharmaceutical diagnostics segments, while outlining a strategic shift towards becoming a comprehensive healthcare solutions provider.

Feb 4, 2026

Business

Niagen Bioscience (NAGE) in Focus: Can Its NAD+ IP and Pending Catalysts Justify a Higher Valuation?

After recent share price declines, Niagen Bioscience is drawing renewed investor scrutiny. The biotech firm's valuation story hinges on its proprietary NAD+ technology, upcoming B2B product launches, and critical clinical data readouts expected later this year.

Feb 4, 2026

Business

GR Life Style's AI Healthcare Ambition: A Bold Pivot or a Pricey Bet?

Hong Kong-listed GR Life Style has inked a strategic deal with Mingzhi Medical Technology to venture into AI-driven oncology and digital health platforms. The move has ignited investor debate, as the company's lofty valuation appears to bank heavily on future potential rather than its current, loss-making fundamentals.

Feb 3, 2026

Business

Healthcare Tech Stocks Show Mixed Q3 Results: Astrana Health Leads Revenue Growth Amid Market Skepticism

The third-quarter earnings season for healthcare technology providers revealed a sector in transition, with companies like Astrana Health posting strong revenue gains but facing investor scrutiny over profitability and guidance. While digital transformation tailwinds persist, adoption challenges and tightening hospital budgets are testing the industry's growth narrative.

Feb 3, 2026

Business

Niagen Bioscience: The Science-Backed Longevity Play Building a Regulatory Fortress

With its patented, FDA-recognized compound Niagen®, Niagen Bioscience (NAGE) has carved out a unique and defensible position at the intersection of nutraceuticals and pharmaceuticals. As the cellular health market expands, the company's dual-channel strategy and deep scientific validation present a compelling growth narrative for investors.

Feb 3, 2026

Business

HCA Healthcare Poised for Growth as Labor Pressures Ease and AI Initiatives Gain Traction

HCA Healthcare, the nation's largest hospital operator, is navigating post-pandemic challenges with a strategy focused on operational efficiency and technology adoption. As labor costs moderate, analysts point to significant margin expansion potential driven by AI deployment across its vast network.

Feb 3, 2026

Business

Tenet Healthcare Takes Full Control of Conifer in $1.9B Deal, Betting Big on Tech Overhaul

Tenet Healthcare has completed a transaction to fully reclaim Conifer Health Solutions, aiming to supercharge the unit's technology and service expansion. The move consolidates a key revenue platform as Tenet rides a multi-year stock surge.

Feb 3, 2026

Business

Healthcare Tech Stocks Navigate Turbulent Q3: Omnicell Surges While Peers Stumble

The third-quarter earnings season revealed a stark divergence in performance among leading healthcare technology providers. While Omnicell impressed with strong results and a soaring stock, peers like Evolent Health and Astrana Health faced significant market headwinds despite revenue beats.

Feb 2, 2026

Business

Catapult Sports Launches Perch P2: A Strategic Move Toward a Holistic Athlete Health Platform

Catapult Sports unveils its next-generation Perch P2 training system, expanding its focus from on-field performance tracking to integrated gym and rehabilitation workflows, as the company aims to build a comprehensive athlete health ecosystem.

Feb 5, 2026

Business

Integra LifeSciences Shareholders Face Steep Losses as Stock Plummets 84% Over Five Years

Long-term investors in Integra LifeSciences Holdings have seen their holdings decimated, with the stock's dramatic decline raising questions about the medical device maker's turnaround prospects and broader sector challenges.

Feb 4, 2026

Business

Twist Bioscience's Rally Raises Valuation Questions: Is the Biotech Stock Running Ahead of Itself?

Twist Bioscience shares have surged over 40% in the past month, reigniting investor debate. While short-term momentum is strong, the stock's long-term performance and a significant gap between its market price and some fair value estimates present a complex picture for the synthetic biology firm.

Feb 4, 2026

Business

Exact Sciences Rides a Wave of Tailwinds to Stellar 2025 Performance

Baron Discovery Fund's latest investor letter spotlights Exact Sciences (EXAS) as a key contributor, buoyed by strong market adoption of its cancer screening tests and favorable industry dynamics, despite the fund's broader quarterly underperformance.

Feb 3, 2026

Business

Twist Bioscience: Silicon DNA Synthesis Leader Nears Profitability Amid Surging Demand

Twist Bioscience's proprietary silicon-based DNA manufacturing platform is driving double-digit revenue growth and margin expansion, positioning the synthetic biology tools provider on a clear path to adjusted EBITDA breakeven by fiscal 2026.

Feb 3, 2026

Business

Edwards Lifesciences Attracts Major Institutional Bet Ahead of Key 2026 Catalysts

A sophisticated, high-conviction options trade by a large investor signals strong confidence in Edwards Lifesciences' fundamentals, with a potential breakout eyed for early 2026 tied to regulatory milestones and sustained growth in its mitral valve business.

Feb 3, 2026

Business

Merck Bets on Precision Oncology with Strategic Eikon Investment and Guardant Health Alliance

Merck & Co. is laying the groundwork for its future in oncology beyond Keytruda, announcing a strategic investment in biotech Eikon Therapeutics and a major collaboration with diagnostic leader Guardant Health. The moves signal a targeted, partnership-driven strategy to bolster its pipeline and diagnostics capabilities in the competitive cancer therapy market.

Feb 2, 2026